Consequently, international guidelines recommend the use of SGLT2 inhibitors in individuals with type 2 diabetes, an eGFR ≥20 ml/min per 1.73 m2 and chronic kidney disease (CKD): i.e. a reduced eGFR (<60 ml/min per 1.73 m2) or albuminuria (urinary albumin/creatinine ratio [uACR] ≥3 mg/mmol) [2, 3]. Here, SLC5A2 is linked to type 2 diabetes mellitus.